Bio-Thera Solutions, Ltd. (SHA:688177)

Market Cap	10.10B
Revenue (ttm)	845.32M
Net Income (ttm)	-368.84M
Shares Out	414.08M
EPS (ttm)	-0.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,136,766
Average Volume	2,260,963
Open	24.84
Previous Close	24.80
Day's Range	24.22 - 24.92
52-Week Range	17.96 - 36.32
Beta	0.58
RSI	48.32
Earnings Date	Apr 28, 2026

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epitheli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 1,266
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688177

Financial Performance

In 2024, Bio-Thera Solutions's revenue was 743.17 million, an increase of 5.44% compared to the previous year's 704.79 million. Losses were -510.30 million, 29.3% more than in 2023.